155 related articles for article (PubMed ID: 29167002)
1. [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments].
Yao S; Gu Y; Zhang Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):737-740. PubMed ID: 29167002
[TBL] [Abstract][Full Text] [Related]
2. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial).
Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D
BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747
[TBL] [Abstract][Full Text] [Related]
3. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
Mencoboni M; Filiberti RA; Taveggia P; Del Corso L; Del Conte A; Covesnon MG; Puccetti C; Donati S; Auriati L; Amoroso D; Camerini A
Anticancer Res; 2017 Jun; 37(6):3189-3194. PubMed ID: 28551663
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.
Kontopodis E; Hatzidaki D; Varthalitis I; Kentepozidis N; Giassas S; Pantazopoulos N; Vardakis N; Rovithi M; Georgoulias V; Agelaki S
J Chemother; 2013 Feb; 25(1):49-55. PubMed ID: 23433445
[TBL] [Abstract][Full Text] [Related]
6. Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.
Barlesi F; Imbs DC; Tomasini P; Greillier L; Galloux M; Testot-Ferry A; Garcia M; Elharrar X; Pelletier A; André N; Mascaux C; Lacarelle B; Cheikh RE; Serre R; Ciccolini J; Barbolosi D
Oncotarget; 2017 Jul; 8(29):47161-47166. PubMed ID: 28525370
[TBL] [Abstract][Full Text] [Related]
7. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
[TBL] [Abstract][Full Text] [Related]
8. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
Banna GL; Camerini A; Bronte G; Anile G; Addeo A; Rundo F; Zanghì G; Lal R; Libra M
Anticancer Res; 2018 Jun; 38(6):3689-3697. PubMed ID: 29848729
[TBL] [Abstract][Full Text] [Related]
9. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
Camerini A; Banna GL; Cinieri S; Pezzuto A; Mencoboni M; Rosetti F; Figueiredo A; Rizzo P; Ricci A; Langenhoven L; Santo A; Addeo A; Amoroso D; Barata F
Clin Transl Oncol; 2019 Jun; 21(6):790-795. PubMed ID: 30448956
[TBL] [Abstract][Full Text] [Related]
10. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
[TBL] [Abstract][Full Text] [Related]
11. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis.
Xu K; Liu T; Zhang J; Zhou Y; Yang F; Ren T
Int J Clin Oncol; 2020 Sep; 25(9):1624-1634. PubMed ID: 32472208
[TBL] [Abstract][Full Text] [Related]
13. A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
Elharrar X; Barbolosi D; Ciccolini J; Meille C; Faivre C; Lacarelle B; André N; Barlesi F
BMC Cancer; 2016 Apr; 16():278. PubMed ID: 27094927
[TBL] [Abstract][Full Text] [Related]
14. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer.
D'Ascanio M; Pezzuto A; Fiorentino C; Sposato B; Bruno P; Grieco A; Mancini R; Ricci A
Biomed Res Int; 2018; 2018():6278403. PubMed ID: 30225260
[TBL] [Abstract][Full Text] [Related]
15. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.
Noronha V; Patil VM; Joshi A; Prabhash K
Indian J Cancer; 2013; 50(2):122-7. PubMed ID: 23979203
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
[TBL] [Abstract][Full Text] [Related]
18. [Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer].
Zhou Y; Xu Y; Zhao J; Zhong W; Wang M
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):351-7. PubMed ID: 26104891
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.
Cremonesi M; Mandalà M; Cazzaniga M; Rezzani C; Gambera M; Barni S
Oncology; 2003; 64(2):97-101. PubMed ID: 12566905
[TBL] [Abstract][Full Text] [Related]
20. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
Pujol JL; Coffy A; Camerini A; Kotsakis A; Mencoboni M; Gusella M; Pasini F; Pezzuto A; Banna GL; Bilir C; Samantas E; Barlesi F; Roch B; Guillou A; Daurès JP
PLoS One; 2019; 14(8):e0220988. PubMed ID: 31430345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
